

CancerVax Landmark Study Results: A Closer Look at Cancer-Cell Killing
CancerVax recently announced a major scientific milestone: its LNP-mRNA technology successfully enabled human antiviral T-cells to kill cancer cells in a laboratory study, achieving up to 100% normalized cancer-cell killing under certain experimental conditions.
Join StartEngine for an exclusive webinar featuring CancerVax CEO Byron Elton, Chief Scientific Officer Dr. George Katibah, and Principal Scientist Dr. Adam Grant as they break down the study results, explain the science behind the company's innovative approach, discuss why these findings are significant, and outline the next steps toward advancing the technology.
Discover what these promising preclinical results mean for CancerVax's mission to develop a potentially universal cancer immunotherapy.
It all takes place Thursday, November 19th, at 10am PT.
Reserve your spot today, and get your questions ready. We look forward to meeting you.
This Reg CF offering is made available through StartEngine Primary, LLC, member FINRA/SIPC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.